Cellosaurus logo
expasy logo

Cellosaurus BL-30 (CVCL_C142)

[Text version]
Cell line name BL-30
Synonyms BL30; BL 30; BL 030; IARC/BL30; IARC/BL 30; IARC-BL30; IARC BL30; IARC BL 30
Accession CVCL_C142
Resource Identification Initiative To cite this cell line use: BL-30 (RRID:CVCL_C142)
Comments From: International Agency of Research on Cancer (IARC); Lyon; France.
Population: Caucasian.
Virology: EBV-negative.
Doubling time: 15-24 hours (Note=Depending on cell density) (DSMZ=ACC-916).
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
Sequence variations
  • Mutation; HGNC; 11998; TP53; Simple; p.Met246Thr (c.737T>C); ClinVar=VCV000428886; Zygosity=Unspecified (PubMed=1915267).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*01:01,11:01
HLA-BB*08:01,39:01
HLA-CC*02:02,07:01
Class II
HLA-DQDQA1*01:03,05:01
DQB1*02:01,06:03
HLA-DRDRB1*03:01,13:01
Disease Burkitt lymphoma (NCIt: C2912)
Burkitt lymphoma (ORDO: Orphanet_543)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_M567 ! BL-28
CVCL_C144 ! BL-32
CVCL_IV21 ! IARC-139
Sex of cell Male
Age at sampling 19Y
Category Cancer cell line
STR profile Source(s): DSMZ

Markers:
AmelogeninX,Y
CSF1PO11,12
D2S133819,24
D3S135817,18
D5S81811
D7S8208,12
D8S117910,13
D13S31711,12
D16S53911,12
D18S5112,13
D19S43313,14
D21S1130,31.2
FGA23,25
Penta D8,9
Penta E12,16
TH016,7
TPOX8,11
vWA14,15

Run an STR similarity search on this cell line
Publications

PubMed=6090749; DOI=10.1093/jnci/73.4.835
Philip I., Philip T., Favrot M.-C., Vuillaume M., Fontaniere B., Chamard D., Lenoir G.M.
Establishment of lymphomatous cell lines from bone marrow samples from patients with Burkitt's lymphoma.
J. Natl. Cancer Inst. 73:835-840(1984)

PubMed=6231253; DOI=10.1002/ijc.2910330407
Ehlin-Henriksson B., Klein G.
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Int. J. Cancer 33:459-463(1984)

PubMed=3934070
Lenoir G.M., Vuillaume M., Bonnardel C.
The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma.
IARC Sci. Publ. 60:309-318(1985)

PubMed=2825176; DOI=10.1073/pnas.84.22.8060
Calender A., Billaud M., Aubry J.-P., Banchereau J., Vuillaume M., Lenoir G.M.
Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells.
Proc. Natl. Acad. Sci. U.S.A. 84:8060-8064(1987)

PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x
Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.
p53 is frequently mutated in Burkitt's lymphoma cell lines.
EMBO J. 10:2879-2887(1991)

PubMed=1356511; DOI=10.1182/blood.V80.7.1781.1781
Gaidano G., Hauptschein R.S., Parsa N.Z., Offit K., Rao P.H., Lenoir G.M., Knowles D.M., Chaganti R.S.K., Dalla-Favera R.
Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma.
Blood 80:1781-1787(1992)

PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993)

PubMed=8896424; DOI=10.1182/blood.V88.9.3562.bloodjournal8893562
Chapman C.J., Zhou J.X., Gregory C.D., Rickinson A.B., Stevenson F.K.
VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection.
Blood 88:3562-3568(1996)

PubMed=9973220
Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G., Magrath I.T., Bhatia K.G.
Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.
Cancer Res. 59:696-703(1999)

PubMed=11793449; DOI=10.1002/gcc.10022
Sobol H., Benziane A., Kerangueven F., Yin L., Noguchi T., Pauly S., Eisinger F., Longy M., Romeo G., Lenoir G.M., Birnbaum D.
Genome-wide search for loss of heterozygosity in Burkitt lymphoma cell lines.
Genes Chromosomes Cancer 33:217-224(2002)

PubMed=22885699; DOI=10.1038/nature11378
Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L., Wright G., Shaffer A.L. III, Hodson D.J., Buras E., Liu X.-L., Powell J.I., Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature 490:116-120(2012)

PubMed=24590883; DOI=10.1002/gcc.22161
Murga Penas E.-M., Schilling G., Behrmann P., Klokow M., Vettorazzi E., Bokemeyer C., Dierlamm J.
Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples.
Genes Chromosomes Cancer 53:497-515(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

Cross-references
Cell line collections (Providers) DSMZ; ACC-916
Cell line databases/resources cancercelllines; CVCL_C142
DSMZCellDive; ACC-916
Encyclopedic resources Wikidata; Q54797136
Polymorphism and mutation databases Cosmic; 2814532
IARC_TP53; 701
Entry history
Entry creation06-Jun-2012
Last entry update05-Oct-2023
Version number20